MLYS vs. APGE, AMPH, TARS, IOVA, IRON, IBRX, WVE, BLTE, GLPG, and ARQT
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Apogee Therapeutics (APGE), Amphastar Pharmaceuticals (AMPH), Tarsus Pharmaceuticals (TARS), Iovance Biotherapeutics (IOVA), Disc Medicine (IRON), ImmunityBio (IBRX), Wave Life Sciences (WVE), Belite Bio (BLTE), Galapagos (GLPG), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry.
Mineralys Therapeutics vs.
Mineralys Therapeutics (NASDAQ:MLYS) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.
Mineralys Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500.
Apogee Therapeutics' return on equity of -21.81% beat Mineralys Therapeutics' return on equity.
84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 33.2% of Mineralys Therapeutics shares are held by insiders. Comparatively, 36.1% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Apogee Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.
Apogee Therapeutics received 10 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users.
Mineralys Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 224.68%. Apogee Therapeutics has a consensus target price of $89.71, indicating a potential upside of 142.08%. Given Mineralys Therapeutics' higher possible upside, research analysts plainly believe Mineralys Therapeutics is more favorable than Apogee Therapeutics.
In the previous week, Mineralys Therapeutics had 6 more articles in the media than Apogee Therapeutics. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 2 mentions for Apogee Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.75 beat Apogee Therapeutics' score of 0.20 indicating that Mineralys Therapeutics is being referred to more favorably in the media.
Summary
Apogee Therapeutics beats Mineralys Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mineralys Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLYS) was last updated on 1/20/2025 by MarketBeat.com Staff
Free MLYS Stock Alerts